Calyx Announces Appointment of New Chief Executive Officer

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES 


Calyx Bio-Ventures Inc. ("Calyx" or the "Company") (TSX VENTURE:CYX) is pleased
to announce that Don Konantz has been appointed President and Chief Executive
Officer. Since December, 2012, Mr. Konantz has served as one of two
Calyx-appointed directors to the board of Agrisoma Biosciences Inc.
("Agrisoma"), a leading-edge agricultural technology company in which Calyx is
the largest shareholder.


Mr. Konantz holds a Masters of Business Administration from the Ivey School at
University of Western Ontario. He brought the College Pro Painters concept to
Winnipeg and after successfully establishing it, moved to Vancouver to scale the
business across the west. Mr. Konantz has thirty years of top management of
dynamic, entrepreneurial companies including such international successful
brands as College Pro and Colorworks. Mr. Konantz has been a consultant to Calyx
for the past 6 months.


"We are very pleased that Don Konantz is joining Calyx as Chief Executive
Officer," commented Hugh Notman, the Company's departing CEO. "His industry
knowledge, background, and strong relationships are an ideal mix of skills to
lead Calyx. His insights, leadership and experience are of significant benefit
to the Company and to Agrisoma." Mr. Notman will remain on Calyx's Board of
Directors.


Don Konantz commented, "I am pleased to join Calyx as President and CEO at this
exciting time. The groundbreaking agricultural technologies of Agrisoma can
translate into significant value for Calyx shareholders and I look forward to
contributing to creating this value."


Concurrently, the Company is pleased to announce a non-brokered private
placement of up to $400,000 (the "Private Placement"). The Private Placement
will consist of the sale of up to 2,666,666 units (a "Unit") at a price of $0.15
per Unit. Each Unit comprises one common share and one common share purchase
warrant. Each common share purchase warrant will entitle the holder to acquire
one additional common share of the Company at a price of $0.35 for a period of
eighteen months from the closing of the Private Placement. The Company expects
that it will pay finders' fees of up to 8% of the gross proceeds raised in cash,
and issue share purchase warrants of up to 8% of the total number of Units
issued in connection with the Private Placement. Subject to the acceptance of
the TSX Venture Exchange, such fiscal advisory fees may be paid in securities in
lieu of cash.


Closing of the Private Placement is anticipated to occur on or before September
12, 2013 and is subject to receipt of applicable regulatory approvals including
approval of the TSX Venture Exchange. The securities issued will be subject to a
standard four-month hold period. The funds raised from the Private Placement
will be used for general working capital and corporate development purposes.


Calyx also announces that it has granted an aggregate of 1,950,000 stock options
to directors, officers, and consultants, pursuant to its Stock Option Plan. Each
stock option is exercisable into one common share of the Company at a price of
$0.20 per share for a period of five years from September 3, 2013. The stock
options are vested immediately, with the exception of stock options issued
pursuant to investor relations activities, which will vest in quarterly
installments over a period of one year in accordance with the policies of the
TSX Venture Exchange.


About Calyx 

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agriculture technology company.
It is the largest shareholder in Agrisoma Biosciences Inc., which is producing a
new proprietary, non-food, energy feedstock crop carinata, which yields oil that
can be refined into transportation fuels that work in existing engines as a 100
percent petroleum substitute. From seed to sky, fuels produced from carinata
substantially reduce carbon and other harmful emissions, and help to reduce
global petroleum dependence. For further information about Calyx, please visit
www.calyxbio.com.


Forward-Looking Statements: This document contains certain forward-looking
statements concerning Calyx, as well as other expectations, plans, goals,
objectives, information or statements about future events, conditions, or
performance that may constitute "forward-looking statements" or "forward-looking
information" under applicable securities legislation. Such statements or
information involve substantial known and unknown risks and uncertainties,
certain of which are beyond Calyx's control, including the completion of the
Private Placement and the delay or failure to receive regulatory approvals.


Such forward-looking statements or information are based on a number of
assumptions, which may prove to be incorrect. In addition to other assumptions
identified in this news release, assumptions have been made regarding, among
other things, timing and completion of the Private Placement, the actual use of
proceeds, and the timing of receipt of regulatory approvals. 


Although Calyx believes that the expectations reflected in such forward-looking
statements or information are reasonable, undue reliance should not be placed on
forward-looking statements because Calyx can give no assurance that such
expectations will prove to be correct. Forward-looking statements or information
are based on current expectations, estimates and projections that involve a
number of risks and uncertainties which could cause actual results to differ
materially from those anticipated by Calyx and described in the forward-looking
statements or information.


The forward-looking statements or information contained in this news release are
made as of the date hereof and Calyx undertakes no obligation to update publicly
or revise any forward-looking statements or information, whether as a result of
new information, future events or otherwise unless so required by applicable
securities laws or the TSX Venture Exchange. The forward-looking statements or
information contained in this news release are expressly qualified by this
cautionary statement.


This press release shall not constitute an offer to sell, nor the solicitation
of an offer to buy, any securities in the United States, nor shall there be any
sale of securities mentioned in this press release in any state in the United
States in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Calyx Bio-Ventures Inc.
Don Konantz
President & CEO
604.649.5961
dkonantz@calyxbio.com


Calyx Bio-Ventures Inc.
Keir Reynolds
Investor Relations
778-998-9242
kreynolds@calyxbio.com
www.calyxbio.com
Calyx Ventures (TSXV:CYX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024